Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Astragaloside IV alleviates liver injury in type 2 diabetes due to promotion of AMPK/mTOR‑mediated autophagy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE
    • Publication Information:
      Original Publication: Athens, Greece : D. A. Spandidos
    • Subject Terms:
      AMP-Activated Protein Kinases/*metabolism ; Autophagy/*drug effects ; Diabetes Mellitus, Type 2/*metabolism ; Liver/*injuries ; Liver/*metabolism ; Saponins/*pharmacology ; TOR Serine-Threonine Kinases/*metabolism ; Triterpenes/*pharmacology; Animals ; Astragalus propinquus ; Diabetes Mellitus, Experimental/metabolism ; Diet, High-Fat ; Glucose/metabolism ; Homeostasis ; Insulin Resistance ; Liver/pathology ; Male ; Oxidative Stress/drug effects ; Quality of Life ; Rats ; Rats, Sprague-Dawley ; Streptozocin/pharmacology
    • Abstract:
      Diabetic liver injury is a serious complication of type 2 diabetes mellitus (T2DM), which is often irreversible in the later stage, and affects the quality of life. Autophagy serves an important role in the occurrence and development of diabetic liver injury. For example, it can improve insulin resistance (IR), dyslipidaemia, oxidative stress and inflammation. Astragaloside IV (AS‑IV) is a natural saponin isolated from the plant Astragalus membranaceus , which has comprehensive pharmacological effects, such as anti‑oxidation, anti‑inflammation and anti‑apoptosis properties, as well as can enhance immunity. However, whether AS‑IV can alleviate diabetic liver injury in T2DM and its underlying mechanisms remain unknown. The present study used high‑fat diets combined with low‑dose streptozotocin to induce a diabetic liver injury model in T2DM rats to investigate whether AS‑IV could alleviate diabetic liver injury and to identify its underlying mechanisms. The results demonstrated that AS‑IV treatment could restore changes in food intake, water intake, urine volume and body weight, as well as improve liver function and glucose homeostasis in T2DM rats. Moreover, AS‑IV treatment promoted suppressed autophagy in the liver of T2DM rats and improved IR, dyslipidaemia, oxidative stress and inflammation. In addition, AS‑IV activated adenosine monophosphate‑activated protein kinase (AMPK), which inhibited mTOR. Taken together, the present study suggested that AS‑IV alleviated diabetic liver injury in T2DM rats, and its mechanism may be associated with the promotion of AMPK/mTOR‑mediated autophagy, which further improved IR, dyslipidaemia, oxidative stress and inflammation. Thus, the regulation of autophagy may be an effective strategy to treat diabetic liver injury in T2DM.
    • References:
      Biomed Pharmacother. 2019 Jan;109:84-92. (PMID: 30396095)
      Acta Pharmacol Sin. 2018 Oct;39(10):1559-1570. (PMID: 29795356)
      Nat Rev Endocrinol. 2018 Feb;14(2):88-98. (PMID: 29219149)
      J Cell Mol Med. 2020 Jan;24(1):671-685. (PMID: 31675186)
      Diabetes. 2016 Nov;65(11):3262-3275. (PMID: 27504012)
      Cell. 2011 Nov 11;147(4):728-41. (PMID: 22078875)
      Pharmacol Res. 2020 Jul;157:104831. (PMID: 32339782)
      Diabetes Metab. 2011 Jun;37(3):179-88. (PMID: 21435930)
      Nat Rev Nephrol. 2016 Dec;12(12):721-737. (PMID: 27748389)
      Cell Metab. 2009 May;9(5):407-16. (PMID: 19416711)
      Oxid Med Cell Longev. 2016;2016:3919627. (PMID: 27656261)
      Free Radic Biol Med. 2019 Nov 1;143:309-323. (PMID: 31369843)
      J Mol Cell Cardiol. 2018 Nov;124:26-34. (PMID: 30292723)
      J Biol Chem. 2007 Dec 28;282(52):37298-302. (PMID: 17986448)
      J Cell Biochem. 2013 Mar;114(3):525-31. (PMID: 22991242)
      Annu Rev Nutr. 2015;35:215-37. (PMID: 26076903)
      ACS Appl Mater Interfaces. 2018 Feb 14;10(6):5227-5239. (PMID: 29359549)
      EBioMedicine. 2016 Nov;13:157-167. (PMID: 27843095)
      J Toxicol Sci. 2019;44(3):167-175. (PMID: 30842369)
      Nat Cell Biol. 2011 Feb;13(2):132-41. (PMID: 21258367)
      Pharm Biol. 2019 Dec;57(1):449-452. (PMID: 31290355)
      Environ Pollut. 2018 Oct;241:1091-1097. (PMID: 30029317)
      Int J Mol Med. 2018 Feb;41(2):1078-1088. (PMID: 29207011)
      Int J Biol Sci. 2015 Apr 02;11(5):559-68. (PMID: 25892963)
      Diabetes Metab Syndr. 2019 Jan - Feb;13(1):364-372. (PMID: 30641727)
      Front Pharmacol. 2018 Apr 16;9:345. (PMID: 29713279)
      J Hepatol. 2013 May;58(5):993-9. (PMID: 23339953)
      Diabetes Obes Metab. 2016 Jun;18(6):549-57. (PMID: 26880114)
      J Int Med Res. 2021 Mar;49(3):300060519841165. (PMID: 33706619)
      Biomed Pharmacother. 2018 Nov;107:721-728. (PMID: 30138894)
      Med Sci Monit. 2019 Nov 26;25:8975-8983. (PMID: 31767824)
      Int Immunopharmacol. 2018 Jan;54:245-253. (PMID: 29161661)
      Cell Metab. 2008 Oct;8(4):318-24. (PMID: 18840362)
      Med Sci Monit. 2019 Jan 29;25:827-835. (PMID: 30734722)
      Cell Metab. 2010 Jun 9;11(6):449-51. (PMID: 20519116)
      Free Radic Biol Med. 2017 Jul;108:725-740. (PMID: 28473248)
      J Gastroenterol. 2013 Apr;48(4):515-25. (PMID: 22911170)
      Pharmacol Res. 2018 Apr;130:93-109. (PMID: 29391233)
      Anesth Analg. 2017 Oct;125(4):1355-1363. (PMID: 28857857)
      Hepatology. 2017 Apr;65(4):1384-1392. (PMID: 27997988)
      Autophagy. 2017;13(11):1952-1968. (PMID: 28853981)
      Oxid Med Cell Longev. 2018 Sep 5;2018:3420187. (PMID: 30254714)
      J Agric Food Chem. 2019 Dec 18;67(50):13948-13959. (PMID: 31698901)
      J Gastroenterol Hepatol. 2015 Mar;30(3):591-9. (PMID: 25250942)
      Obesity (Silver Spring). 2017 Mar;25(3):561-571. (PMID: 28145056)
      J Biol Chem. 2015 Mar 6;290(10):6071-85. (PMID: 25548282)
      Oxid Med Cell Longev. 2018 Sep 23;2018:8284107. (PMID: 30344887)
      Diabetes Res Clin Pract. 2014 Apr;104(1):53-62. (PMID: 24485856)
      Sci Rep. 2017 Jul 31;7(1):6852. (PMID: 28761152)
      Biomed Pharmacother. 2020 Jul;127:110081. (PMID: 32244194)
      Cell Physiol Biochem. 2017;43(3):1168-1187. (PMID: 28977784)
      J Biol Chem. 2009 Nov 6;284(45):31484-92. (PMID: 19758991)
      J Clin Exp Hepatol. 2019 Sep-Oct;9(5):607-618. (PMID: 31695251)
      Life Sci. 2005 Sep 30;77(20):2594-602. (PMID: 15964033)
    • Contributed Indexing:
      Keywords: AS‑IV; diabetic liver injury; autophagy; AMPK; mTOR
    • Accession Number:
      0 (Saponins)
      0 (Triterpenes)
      3A592W8XKE (astragaloside A)
      5W494URQ81 (Streptozocin)
      EC 2.7.1.1 (mTOR protein, rat)
      EC 2.7.11.1 (TOR Serine-Threonine Kinases)
      EC 2.7.11.31 (AMP-Activated Protein Kinases)
      IY9XDZ35W2 (Glucose)
    • Publication Date:
      Date Created: 20210413 Date Completed: 20211018 Latest Revision: 20211204
    • Publication Date:
      20240513
    • Accession Number:
      PMC8060804
    • Accession Number:
      10.3892/mmr.2021.12076
    • Accession Number:
      33846768